Oxford Nanopore Technologies shares rose 8.02% today to 215.4p, a gain of 16p, according to the market data provided. The move values the group at around £1.95 billion and extends a powerful run that saw the shares close up more than 9% at 199.4p …
In a regulatory announcement at 07:00 on 29 September 2026, AstraZeneca said it will invest $2bn in newly issued stock of Summit Therapeutics. The company will buy approximately 109 thousand shares of preferred stock, each convertible into Summit common stock at a 1:1,000 ratio.
LSE:ONT is one of the UK's most prominent life sciences technology companies. It develops nanopore-based sensing technology that can read DNA and RNA in real time, with applications across research, clinical diagnostics, biopharma, and applied markets such as food safety and infectious disease surveillance. …
LSE:SBTX has faced a turbulent 2026. The life science company, which focuses on skin health and the gut-skin axis, saw its chief executive suspended and then resign in February amid a board investigation into his conduct. An independent investigation followed, and in April the …
• H1 2026Revenueincreased 42% to $30.4 million and the company remained on track for operating profitability during 2026.
The move came on a day when theBlue-Chipindexfell 0.45%, pressured by soaring US bond yields and weaker energy stocks. Against that uncertain backdrop, investors gravitated toward defensive names with steady,Recurring Revenuestreams, and LSE:CTEC fitted that profile well.
On 29 September 2026 Solvonis Therapeutics plc (LSE:SVNS) released new analyses of data from KARE, a randomised Phase 2 trial of adjunctive ketamine in alcohol use disorder (AUD) led by Professor Celia Morgan at the University of Exeter. Solvonis uses the trial data for …
On 29 September 2026 Thalia Therapeutics plc (LSE:THAT) said a new patent had been granted in China for miRisten (THAT-001), an anti-microRNA-126 therapeutic being developed initially for patients with acute myeloid leukaemia (AML), which the company describes as an aggressive blood cancer with significant …
On 29 September 2026 Abingdon Health plc (LSE:ABDX) said that Abingdon Analytical Ltd, the group's performance evaluation laboratory based in Doncaster, UK, had been granted accreditation to ISO/IEC 17025:2017 by the United Kingdom Accreditation Service (UKAS).
Oxford Nanopore Technologies gained 9.26% on 29 September, extending a strong late-September trading pattern. The company remains closely watched because its long-read sequencing technology addresses applications across genomics, clinical research, infectious disease surveillance and life-science research.